Document is current
Any future updates will be listed below
-
Authors
Saydam, O
Ozgen Saydam, B
Adiyaman, SC
Sonmez Ince, M
Eren, MA
Keskin, FE
Bilen, H
Dagdeviren, M
Kaya, S
Akinci, G
Balci, A
Altay, C
Bayraktar, F
Oral, EA
Akinci, B
-
Funding
Funding for this research was provided by:
University of Michigan (NA)
Turkiye Egitim Vakfi (NA)
- License Information
-
More Information
Article History
Received: 16 March 2021
Accepted: 29 July 2021
First Online: 1 October 2021
Declarations
:
: The research use of the data collected was approved by the Institutional Review Board (IRB) of the Dokuz Eylul University, Izmir, Turkey.
: For this retrospective study, data were collected under the oversight of Dokuz Eylul University Ethics Committee. Patients gave consent to use anonymous data for research purposes. The images used in the manuscript are entirely unidentifiable and there are no personal details on individuals reported within the manuscript.
: EAO reports the following conflicts: Grant support: Aegerion Pharmaceuticals (now Amryt Pharma), Ionis Pharmaceuticals, Akcea Therapeutics, Gemphire Therapeutics, GI Dynamics (current), AstraZeneca (past two years). Consultant or Advisor: AstraZeneca, Thera Therapeutics, and BMS (past), Aegerion Pharmaceuticals (now Amryt Pharma), Regeneron Pharmaceuticals (current). Drug support: Aegerion Pharmaceuticals (now Amryt Pharma), Akcea Therapeutics, Rhythm Pharmaceuticals (all current). Other support: Aegerion Pharmaceuticals (now Amryt Pharma), Regeneron Pharmaceuticals (current). BA has attended Scientific Advisory Board Meetings organized by Aegerion Pharmaceuticals (now Amryt Pharma) and Regeneron Pharmaceuticals and has received honoraria as a speaker from AstraZeneca, Lilly, MSD, Novartis, Novo Nordisk, Boehringer-Ingelheim, Servier, and Sanofi-Aventis. Other authors report no conflicts of interest.
